
Similar Posts

Ultragenyx CEO talks the company’s path to profitability in developing drugs for rare diseases
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Dr. Emil Kakkis, Ultragenyx founder & CEO, joins ‘Closing Bell Overtime’ to talk drug trials and development, its path to profitability and more.

The number one thing we’re concerned about is summer traffic demand, says Cowen’s airline analyst
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Helane Becker, Cowen, joins ‘Squawk on the Street’ to discuss what Delta’s earnings results say about the airline industry, what she’s watching and headwinds for the industry. 03:43 Mon, Apr 18 202211:40 AM EDT

5 things you don’t know about your 401(k)
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email Investing in a 401(k) is vital for us to make sure we are set for the future but here are some things you may have not known about your 401(k). CNBC’s Landon Dowdy zeros in on what you need to know. 01:54…

1-on-One: Shanette, New York
Shanette’s dream home has become a financial nightmare. She’s come to Suze to ask for advice on how to get back on track.

CVS to close ‘select’ pharmacies in Target stores starting in February
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email CNBC’s Bertha Coombs joins ‘Closing Bell’ to report on the announcement from CVS on their plan to close select pharmacies inside Target locations beginning in February.

I held onto Intel too long, says MarketRebellion.com’s Jon Najarian
ShareShare Article via FacebookShare Article via TwitterShare Article via LinkedInShare Article via Email The ‘Halftime Report’ investment committee — Steve Weiss, Pete Najarian, Joe Terranova and Karen Firestone — discuss CITI’s bearish call on Intel and the company’s outlook. 02:19 Wed, Jun 8 20221:08 PM EDT